Link to DermNet's pages about injected skin treatments.
- Adalimumab
- Adrenaline
- Afamelanotide
- Alefacept
- Anakinra
- Anaesthetics
- Antibiotics
- Augmentation
- Biological agents for psoriasis
- Biological treatments
- Bleomycin
- Botulinum toxin
- Brodalumab
- Cemiplimab
- Collagen replacement
- Cyclophosphamide
- Deoxycholic acid
- Dupilumab
- Efalizumab
- Etanercept
- Facial implants
- Fat grafting
- Fillers
- Gold
- Guselkumab
- Hyaluronic acid implant
- Hydroxyapatite implant
- Immunoglobulin
- Immunotherapy for allergic diseases
- Immunotherapy for melanoma metastases
- Implants
- Infliximab
- Intralesional injection
- Intralesional steroids
- Ipilimumab
- Isolated limb perfusion
- Ixekizumab
- Lanadelumab
- Lebrikizumab
- Leg vein therapies
- Local anaesthetics
- Melanotan II
- Nivolumab
- Mesotherapy
- Omalizumab
- Pembrolizumab
- Platelet-rich plasma
- Polyacrylamide implants
- Polyethylene implants
- Polymethyl methacrylate implants
- Polytetrafluoroethylene implant
- Posaconazole
- Risankizumab
- Rituximab
- Sclerotherapy
- Secukinumb
- Silicone implant
- Tildrakizumab
- Ustekinumab
- Vaccines for melanoma
Approved datasheets are the official source of information for medicines, including approved uses, doses, and safety information. Check the individual datasheet in your country for information about medicines.
We suggest you refer to your national drug approval agency such as the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA), UK Medicines and Healthcare products regulatory agency (MHRA) / emc, and NZ Medsafe, or a national or state-approved formulary eg, the New Zealand Formulary (NZF) and New Zealand Formulary for Children (NZFC) and the British National Formulary (BNF) and British National Formulary for Children (BNFC).